ELOX Stock Forecast: Eloxx Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Eloxx Pharmaceuticals, Inc. is $39. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 18 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Eloxx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (82): The shares have been drifting up relative to others.
Accruals (5): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ELOX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ELOX, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Of the 20 most recent actions, 1 moved their price target up and 7 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Oct 2026 | Guggenheim | Maintains | Buy | $43 → $40 |
| 15 Oct 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 18 Sept 2026 | Leerink Partners | Initiates | Outperform | $32 |
| 24 Aug 2026 | Guggenheim | Reiterates | Buy | $43 |
| 20 Aug 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | $38 |
| 22 July 2026 | LifeSci Capital | Initiates | Outperform | $40 |
| 20 July 2026 | Guggenheim | Initiates | Buy | $43 |
| 11 July 2023 | Oppenheimer | Maintains | Outperform | $50 → $55 |
| 6 Apr 2023 | Oppenheimer | Reiterates | Outperform | — |
| 23 May 2022 | Piper Sandler | Maintains | Overweight | $4.00 → $1.50 |
| 9 May 2022 | HC Wainwright & Co. | Maintains | Neutral | $1.00 → $0.50 |
| 17 Dec 2021 | Oppenheimer | Initiates | Outperform | — |
| 18 Nov 2021 | HC Wainwright & Co. | Maintains | Neutral | $2.00 → $1.00 |
| 11 Nov 2021 | HC Wainwright & Co. | Maintains | Neutral | $3.00 → $2.00 |
| 30 June 2021 | Mizuho | Initiates | Buy | — |
| 27 May 2021 | B. Riley Securities | Initiates | Buy | — |
| 11 June 2020 | Citigroup | Downgrade | Neutral | $11 → $4.00 |
| 8 May 2020 | Janney Capital | Maintains | Buy | — |
| 8 May 2020 | Janney Montgomery Scott | Maintains | Buy | $13 → $10 |
| 6 Mar 2020 | H.C. Wainwright | Reiterates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ELOX.
This page is one stock. Monday covers all of them.
ELOX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ELOX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 5.6×
- Price / sales
- —
- Price / book
- 1.1×
- EV / EBITDA
- —
Cheaper than 85% of US stocks
Cheaper than 68% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −113.8%
- Dividend yield
- —
Higher than 2% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Eloxx Pharmaceuticals, Inc. has a market value of $43.7M.
Trailing P/E: 5.6×.
Eloxx Pharmaceuticals, Inc. employs 10 people.
Data provided by Twelve Data
ELOX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ELOX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Eloxx Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ELOX
What is the ELOX stock price forecast for 2026-2027?
The median 12-month analyst price target for Eloxx Pharmaceuticals, Inc. is $39, with estimates ranging from $32 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ELOX stock a buy right now?
Of the 5 analysts covering Eloxx Pharmaceuticals, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Eloxx Pharmaceuticals, Inc. 18 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ELOX?
As at 21 Nov 2026, Eloxx Pharmaceuticals, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (82 of 100).
Will ELOX stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $39, and Ticker Nerd's factor model ranks Eloxx Pharmaceuticals, Inc. 18 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ELOX stock forecast for 2030?
No analyst covering Eloxx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELOX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $40 over the next 12 months.
What does Eloxx Pharmaceuticals, Inc. do?
Eloxx Pharmaceuticals, Inc. Common Stock represents equity in Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel small-molecule medicines that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations. The company’s current pipeline centers on exaluren, which is being studied for rare kidney diseases such as nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease, along with related ultra-rare genetic conditions.
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc. Common Stock represents equity in Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel small-molecule medicines that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations. The company’s current pipeline centers on exaluren, which is being studied for rare kidney diseases such as nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease, along with related ultra-rare genetic conditions. Eloxx also has a licensed program, ZKN-013, being advanced for rare dermatological diseases associated with nonsense mutations. Headquartered in Arlington, Massachusetts, Eloxx Pharmaceuticals operates in the biotechnology sector and serves a specialized niche in precision therapies for rare and ultra-rare disorders.
CEO Mr. Sumit Aggarwal M.B.A. · 10 employees · United States · https://www.eloxxpharma.com